Prelude Therapeutics announced preclinical data on PRT13722, a first-in-class, orally bioavailable, potent, and highly selective KAT6A degrader, at the AACR Annual Meeting 20261.
PRT13722 showed complete responses as monotherapy in multiple CDX and PDX models of HR+/HER2- breast cancer, with a differentiated efficacy and improved hematological safety profile compared to dual KAT6A/B inhibitors1.
The company remains on track to file an IND application for PRT13722 in mid-2026 and initiate clinical trials in the second half of 20261.
Poster presentation titled 'First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile' is scheduled for April 21, 2026, at 2:
00 PM PT1.
Sources:
1. https://www.biospace.com/press-releases/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026